A major goal of this program is to improve the sensitivity and specificity of diagnosis in the common pediatric tumors through application of molecular biological techniques. An additional goal is to use pediatric tumor specimens to define molecular process which contribute to the malignant phenotype of childhood solid tumors. Common childhood tumors that will be studied include acute lymphoblastic leukemia, Wilms tumor, neuroblastoma, medulloblastoma, rhabdomyosarcoma and osteogenic sarcoma. Project 1 will utilize specific oligonucleotide probes, which recognize the CDR3 region of the IgH locus of the leukemic clone, to quantify the number of leukemic cells in the bone marrow and peripheral blood of patients with subclinical disease. It will be learned if the presence of large numbers of leukemic cells are predictive of relapse after induction- or during maintenance-chemotherapy. Project 2 characterizes the Wilms tumor zinc finger protein in tumor samples by the ability to bind to a specific DNA sequence and regulate transcription. Project 3 will identify and characterize NGF induced immediate-early genes in primitive neuroectodermal tumors which are incompetent to trans activity other genes whose expression is required for terminal differentiation. Project 4 identifies and clones the t(2;13) translocation breakpoint characteristic of alveolar rhabdomyosarcoma because this translocation likely contributes to tumorigenicity. Project 5 identifies osteosarcomas which produce PDGF and learns if endogenous PDGF production causes osteosarcomas to grow in an autocrine fashion. It also identifies genes and transduction mechanisms which are impaired in those osteosarcomas which don't respond to PDGF.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047983-06
Application #
2092808
Study Section
Special Emphasis Panel (SRC (T1))
Project Start
1988-09-30
Project End
1995-07-31
Budget Start
1993-08-01
Budget End
1995-07-31
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moshier, J A; Skunca, M; Wu, W et al. (1996) Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res 24:1149-57
Macina, R A; Barr, F G; Galili, N et al. (1995) Genomic organization of the human PAX3 gene: DNA sequence analysis of the region disrupted in alveolar rhabdomyosarcoma. Genomics 26:1-8
Ryan, G; Steele-Perkins, V; Morris, J F et al. (1995) Repression of Pax-2 by WT1 during normal kidney development. Development 121:867-75
Morris, J F; Rauscher 3rd, F J; Davis, B et al. (1995) The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86:3640-7
Barr, F G; Chatten, J; D'Cruz, C M et al. (1995) Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 273:553-7
Bennicelli, J L; Fredericks, W J; Wilson, R B et al. (1995) Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-30
Biegel, J A; Nycum, L M; Valentine, V et al. (1995) Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization. Genes Chromosomes Cancer 12:186-92
Fredericks, W J; Galili, N; Mukhopadhyay, S et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15:1522-35
Amin, K M; Litzky, L A; Smythe, W R et al. (1995) Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-56
Werner, H; Shen-Orr, Z; Rauscher 3rd, F J et al. (1995) Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15:3516-22

Showing the most recent 10 out of 75 publications